Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Tax Provisions (2022 - 2026)

TriSalus Life Sciences has reported Tax Provisions over the past 5 years, most recently at $4000.0 for Q1 2026.

  • For Q1 2026, Tax Provisions fell 20.0% year-over-year to $4000.0; the TTM value through Mar 2026 reached $6000.0, down 25.0%, while the annual FY2025 figure was $7000.0, 16.67% up from the prior year.
  • Tax Provisions for Q1 2026 was $4000.0 at TriSalus Life Sciences, down from $5000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $28202.0 in Q2 2022 and troughed at -$5000.0 in Q1 2023.
  • A 5-year average of $4630.9 and a median of $4000.0 in 2026 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: crashed 200.0% in 2024 and later surged 266.67% in 2025.
  • Year by year, Tax Provisions stood at $6000.0 in 2022, then tumbled by 83.33% to $1000.0 in 2023, then crashed by 200.0% to -$1000.0 in 2024, then surged by 600.0% to $5000.0 in 2025, then fell by 20.0% to $4000.0 in 2026.
  • Business Quant data shows Tax Provisions for TLSI at $4000.0 in Q1 2026, $5000.0 in Q3 2025, and -$3000.0 in Q2 2025.